Versek, Craig William; Banijamali, Mohammad Ali S; Bex, Peter J; Lashkari, Kameran; Kamarthi, Sagar V; Sridhar, Srinivas
Portable Objective Diagnostics using Visual Evoked Potentials for Age-related Macular Degeneration Journal Article
In: medRxiv, 2020.
@article{versek2020portable,
title = {Portable Objective Diagnostics using Visual Evoked Potentials for Age-related Macular Degeneration},
author = {Craig William Versek and Mohammad Ali S Banijamali and Peter J Bex and Kameran Lashkari and Sagar V Kamarthi and Srinivas Sridhar},
year = {2020},
date = {2020-01-01},
journal = {medRxiv},
publisher = {Cold Spring Harbor Laboratory Press},
abstract = {Delayed Dark Adapted vision Recovery (DAR) is a biomarker for Age-related Macular Degeneration (AMD); however, its measurement is burdensome for patients and examiners. We developed a portable, wireless, quick-setup system that employs a headset with a smartphone to deliver and analyze controlled dichoptic photobleach and pattern reversal stimuli, and with custom electroencephalography (EEG) electrodes, to measure objective Dark Adapted Visual Evoked Potentials (DAVEP) at multiple locations of the visual field in one comfortable 20-minute session, without requiring subject reporting. DAVEP responses post photobleach (up to 15 minutes), were measured concurrently in both eyes of 13 patients with AMD and 8 others not diagnosed with AMD. New unexpected features were observed in the DAVEP responses at high latencies to scotopic stimulus intensities. The amplitude recovery of the DAVEP response was significantly delayed in AMD patients compared with controls. We developed DAVEP1 scores, a simple metric for DAR, using it to successfully identify all 100% of AMD subjects and correctly classify 90% of subject eyes. Deficits in DAR in patients with AMD can be identified with this objective VEP based system using the DAVEP1 metric, a promising new objective biomarker for this disease that can be easily tested in a clinic.},
keywords = {Neurotechnology, Opthalmology},
pubstate = {published},
tppubtype = {article}
}
Delayed Dark Adapted vision Recovery (DAR) is a biomarker for Age-related Macular Degeneration (AMD); however, its measurement is burdensome for patients and examiners. We developed a portable, wireless, quick-setup system that employs a headset with a smartphone to deliver and analyze controlled dichoptic photobleach and pattern reversal stimuli, and with custom electroencephalography (EEG) electrodes, to measure objective Dark Adapted Visual Evoked Potentials (DAVEP) at multiple locations of the visual field in one comfortable 20-minute session, without requiring subject reporting. DAVEP responses post photobleach (up to 15 minutes), were measured concurrently in both eyes of 13 patients with AMD and 8 others not diagnosed with AMD. New unexpected features were observed in the DAVEP responses at high latencies to scotopic stimulus intensities. The amplitude recovery of the DAVEP response was significantly delayed in AMD patients compared with controls. We developed DAVEP1 scores, a simple metric for DAR, using it to successfully identify all 100% of AMD subjects and correctly classify 90% of subject eyes. Deficits in DAR in patients with AMD can be identified with this objective VEP based system using the DAVEP1 metric, a promising new objective biomarker for this disease that can be easily tested in a clinic.
Cheng, Ming J; Mitra, Ronodeep; Okorafor, Chinedu C; Nersesyan, Alina A; Harding, Ian C; Bal, Nandita N; Kumar, Rajiv; Jo, Hanjoong; Sridhar, Srinivas; Ebong, Eno E
Targeted Intravenous Nanoparticle Delivery: Role of Flow and Endothelial Glycocalyx Integrity Journal Article
In: Annals of Biomedical Engineering, pp. 1–14, 2020.
@article{cheng2020targeted,
title = {Targeted Intravenous Nanoparticle Delivery: Role of Flow and Endothelial Glycocalyx Integrity},
author = {Ming J Cheng and Ronodeep Mitra and Chinedu C Okorafor and Alina A Nersesyan and Ian C Harding and Nandita N Bal and Rajiv Kumar and Hanjoong Jo and Srinivas Sridhar and Eno E Ebong},
year = {2020},
date = {2020-01-01},
journal = {Annals of Biomedical Engineering},
pages = {1--14},
abstract = {Therapies for atherosclerotic cardiovascular disease should target early disease stages and specific vascular sites where disease occurs. Endothelial glycocalyx (GCX) degradation compromises endothelial barrier function and increases vascular permeability. This initiates pro-atherosclerotic lipids and inflammatory cells to penetrate vessel walls, and at the same time this can be leveraged for targeted drug delivery. In prior cell culture studies, GCX degradation significantly increased endothelial cell uptake of nanoparticle vehicles that are designed for drug delivery, compared to the effects of intact GCX. The present study assessed if the cell culture findings translate to selective nanoparticle uptake in animal vessels. In mice, the left carotid artery (LCA) was partially ligated to disturb blood flow, which induces GCX degradation, endothelial dysfunction, and atherosclerosis. After ligation, the LCA vessel wall exhibited.},
keywords = {Nanomedicine},
pubstate = {published},
tppubtype = {article}
}
Therapies for atherosclerotic cardiovascular disease should target early disease stages and specific vascular sites where disease occurs. Endothelial glycocalyx (GCX) degradation compromises endothelial barrier function and increases vascular permeability. This initiates pro-atherosclerotic lipids and inflammatory cells to penetrate vessel walls, and at the same time this can be leveraged for targeted drug delivery. In prior cell culture studies, GCX degradation significantly increased endothelial cell uptake of nanoparticle vehicles that are designed for drug delivery, compared to the effects of intact GCX. The present study assessed if the cell culture findings translate to selective nanoparticle uptake in animal vessels. In mice, the left carotid artery (LCA) was partially ligated to disturb blood flow, which induces GCX degradation, endothelial dysfunction, and atherosclerosis. After ligation, the LCA vessel wall exhibited.
Sridhar, Srinivas; Versek, Craig; Bex, Peter
Portable brain and vision diagnostic and therapeutic system Miscellaneous
2019, (US Patent App. 16/347,049).
@misc{sridhar2019portableb,
title = {Portable brain and vision diagnostic and therapeutic system},
author = {Srinivas Sridhar and Craig Versek and Peter Bex},
year = {2019},
date = {2019-10-01},
abstract = {A portable wireless neuromonitoring device can be used to diagnose and/or treat conditions of the brain and vision system. The device includes a sensor unit mountable on the head of a human subject and capable of recording signals from the brain in EEG and/or EFEG (electric field encephalography) mode, and the device can be used for simultaneous stimulus display and recording with latency of less than 1 millisecond. The device also includes electrodes that allow rapid set-up and measurement with low impedance contact with the scalp. The device can also be used in conjunction with virtual reality or alternate reality environments.},
note = {US Patent App. 16/347,049},
keywords = {Neurotechnology, Opthalmology},
pubstate = {published},
tppubtype = {misc}
}
A portable wireless neuromonitoring device can be used to diagnose and/or treat conditions of the brain and vision system. The device includes a sensor unit mountable on the head of a human subject and capable of recording signals from the brain in EEG and/or EFEG (electric field encephalography) mode, and the device can be used for simultaneous stimulus display and recording with latency of less than 1 millisecond. The device also includes electrodes that allow rapid set-up and measurement with low impedance contact with the scalp. The device can also be used in conjunction with virtual reality or alternate reality environments.
View All Publications
